|
|
||||||||||
|
J Am Coll Cardiol, 2002; 40:1723-1730 © 2002 by the American College of Cardiology Foundation |
* Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
Manuscript received March 20, 2002; revised manuscript received August 1, 2002, accepted August 26, 2002.
* Reprint requests and correspondence: Dr. Maurice Enriquez-Sarano, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Sarano.Maurice{at}mayo.edu
OBJECTIVES: This study was designed to analyze the association among cholesterol levels, lipid-lowering treatment, and progression of aortic stenosis (AS) in the community.
BACKGROUND: Aortic stenosis is a progressive disease for which there is no known medical treatment to prevent or slow progression. Despite plausible pathologic mechanisms linking hypercholesterolemia to AS progression, clinical studies have been inconsistent and affected by referral bias, and the role of lipid-lowering therapy is uncertain.
METHODS: We determined the association between blood cholesterol levels and progression of native AS (assessed by Doppler echocardiography at baseline and at least six months later; mean interval, 3.7 ± 2.3 years) in a community-based study of 156 patients (age 77 ± 12 years; 90 men). Thirty-eight patients received statin treatment during follow-up.
RESULTS: In untreated subjects, mean gradient increased from 22 ± 12 mm Hg to 39 ± 19 mm Hg, and aortic valve area (AVA) decreased from 1.20 ± 0.35 cm2 to 0.91 ± 0.33 cm2 (both p < 0.001). The annualized change in AVA was 0.09 ± 0.17 cm2/year (7% ± 13%/year). Neither total cholesterol (r = 0.01, p = 0.92) nor low-density lipoprotein cholesterol (r = 0.01; p = 0.88) showed a significant correlation to AS progression. Nevertheless, progression of AS was slower in patients receiving statins compared with untreated patients (decrease in AVA 3 ± 10% vs. 7 ± 13% per year, respectively; p = 0.04), even when adjusted for age, gender, cholesterol, and baseline valve area (p = 0.04). The association of statin treatment with slower progression was confirmed when analysis was restricted to patients coming for a systematic follow-up (p=0.02). The odds ratio of AS progression with statin treatment was 0.46 (95% confidence interval, 0.21 to 0.96).
CONCLUSIONS: In the community, progression of AS shows no trend of association with cholesterol levels. Statin treatment, however, is associated with slower progression, suggesting that the effects of statin treatment on progression of AS should be pursued with appropriate clinical trials.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
B. A. Carabello Aortic Stenosis: It Is a Hot Topic: The Link to Coronary Artery Disease J. Am. Coll. Cardiol., August 26, 2008; 52(9): 764 - 766. [Full Text] [PDF] |
||||
![]() |
C. E. Tourmousoglou, S. Lalos, and T. Psarros Do statins slow the progression of aortic valve stenosis? Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 684 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves J. Lipid Res., July 1, 2008; 49(7): 1511 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Pedersen Overview of clinical trials on calcific aortic stenosis Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E31 - E40. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al. Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Arch Intern Med, June 9, 2008; 168(11): 1200 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Jassal, J. W. Tam, K. M. Bhagirath, I. Gaboury, R. A. Sochowski, J. G. Dumesnil, P. J. Giannoccaro, J. Jue, A. S. Pandey, C. D. Joyner, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study Eur. Heart J., June 2, 2008; 29(12): 1542 - 1547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pachon and J. Zamorano Mitral annular calcifications and aortic valve stenosis Eur. Heart J., June 2, 2008; 29(12): 1478 - 1480. [Full Text] [PDF] |
||||
![]() |
M. Enriquez-Sarano, V. T. Nkomo, and H. Michelena Principles and Practice of Echocardiography in Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 315 - 348. [Full Text] |
||||
![]() |
D. Mohty, P. Pibarot, J.-P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 187 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Messika-Zeitoun, L. F. Bielak, P. A. Peyser, P. F. Sheedy, S. T. Turner, V. T. Nkomo, J. F. Breen, J. Maalouf, C. Scott, A. J. Tajik, et al. Aortic Valve Calcification: Determinants and Progression in the Population Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 642 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Griffin Statins in Aortic Stenosis: New Data From a Prospective Clinical Trial J. Am. Coll. Cardiol., February 6, 2007; 49(5): 562 - 564. [Full Text] [PDF] |
||||
![]() |
L. M. Moura, S. F. Ramos, J. L. Zamorano, I. M. Barros, L. F. Azevedo, F. Rocha-Goncalves, and N. M. Rajamannan Rosuvastatin Affecting Aortic Valve Endothelium to Slow the Progression of Aortic Stenosis J. Am. Coll. Cardiol., February 6, 2007; 49(5): 554 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, G. Filippatos, F. Flachskampf, R. Hall, B. Iung, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur. Heart J., January 26, 2007; (2007) ehl428v1. [Full Text] [PDF] |
||||
![]() |
D. Chua and K. Kalb Statins and Progression of Calcified Aortic Stenosis Ann. Pharmacother., December 1, 2006; 40(12): 2195 - 2199. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Johnson, J. A. Leopold, and J. Loscalzo Vascular Calcification: Pathobiological Mechanisms and Clinical Implications Circ. Res., November 10, 2006; 99(10): 1044 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
J R Ortlepp, M Pillich, V Mevissen, C Krantz, M Kimmel, R Autschbach, G Langebartels, J Erdmann, R Hoffmann, and K Zerres APOE alleles are not associated with calcific aortic stenosis Heart, October 1, 2006; 92(10): 1463 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF] |
||||
![]() |
K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Briand, I. Lemieux, J. G. Dumesnil, P. Mathieu, A. Cartier, J.-P. Despres, M. Arsenault, J. Couet, and P. Pibarot Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2229 - 2236. [Abstract] [Full Text] [PDF] |
||||
![]() |
D E Newby, S J Cowell, and N A Boon Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart, June 1, 2006; 92(6): 729 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Liebe, M. Brueckmann, M. Borggrefe, and J. J. Kaden Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J., April 1, 2006; 27(7): 773 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Skowasch, S Schrempf, C J Preusse, J A Likungu, A Welz, B Luderitz, and G Bauriedel Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins Heart, April 1, 2006; 92(4): 495 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Skowasch, S. Schrempf, N. Wernert, M. Steinmetz, A. Jabs, I. Tuleta, U. Welsch, C. J. Preusse, J. A. Likungu, A. Welz, et al. Cells of primarily extravalvular origin in degenerative aortic valves and bioprostheses Eur. Heart J., December 1, 2005; 26(23): 2576 - 2580. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Baumgartner Aortic stenosis: medical and surgical management Heart, November 1, 2005; 91(11): 1483 - 1488. [Full Text] [PDF] |
||||
![]() |
D. Weisenberg, Y. Sahar, G. Sahar, Y. Shapira, Z. Iakobishvili, B. A. Vidne, and A. Sagie Atherosclerosis of the aorta is common in patients with severe aortic stenosis: An intraoperative transesophageal echocardiographic study J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 29 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Pellikka, M. E. Sarano, R. A. Nishimura, J. F. Malouf, K. R. Bailey, C. G. Scott, M. E. Barnes, and A. J. Tajik Outcome of 622 Adults With Asymptomatic, Hemodynamically Significant Aortic Stenosis During Prolonged Follow-Up Circulation, June 21, 2005; 111(24): 3290 - 3295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Cowell, D. E. Newby, R. J. Prescott, P. Bloomfield, J. Reid, D. B. Northridge, N. A. Boon, and the Scottish Aortic Stenosis and Lipid Lowering Tr A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis N. Engl. J. Med., June 9, 2005; 352(23): 2389 - 2397. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rosenhek Statins for Aortic Stenosis N. Engl. J. Med., June 9, 2005; 352(23): 2441 - 2443. [Full Text] [PDF] |
||||
![]() |
D. W. Quinn Jr. and S. A. Spinler Efficacy of statins in preventing progression of aortic stenosis Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 979 - 981. [Full Text] [PDF] |
||||
![]() |
J. S. Borer Aortic Stenosis and Statins: More Evidence of "Pleotropy"? Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 476 - 477. [Full Text] [PDF] |
||||
![]() |
W. C. Roberts and J. M. Ko Frequency by Decades of Unicuspid, Bicuspid, and Tricuspid Aortic Valves in Adults Having Isolated Aortic Valve Replacement for Aortic Stenosis, With or Without Associated Aortic Regurgitation Circulation, February 22, 2005; 111(7): 920 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y.-M. Wang, S. S.-Y. Ho, M. Wang, E. K.-H. Liu, S. Ho, P. K.-T. Li, S.-F. Lui, and J. E. Sanderson Cardiac Valvular Calcification as a Marker of Atherosclerosis and Arterial Calcification in End-stage Renal Disease Arch Intern Med, February 14, 2005; 165(3): 327 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
Systolic murmur in an asymptomatic 70 year old man Heart, January 1, 2005; 91(1): 125 - 125. [Full Text] [PDF] |
||||
![]() |
S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Rajamannan and C. M. Otto Targeted Therapy to Prevent Progression of Calcific Aortic Stenosis Circulation, September 7, 2004; 110(10): 1180 - 1182. [Full Text] [PDF] |
||||
![]() |
R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis Circulation, September 7, 2004; 110(10): 1291 - 1295. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Messika-Zeitoun, M.-C. Aubry, D. Detaint, L. F. Bielak, P. A. Peyser, P. F. Sheedy, S. T. Turner, J. F. Breen, C. Scott, A. J. Tajik, et al. Evaluation and Clinical Implications of Aortic Valve Calcification Measured by Electron-Beam Computed Tomography Circulation, July 20, 2004; 110(3): 356 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. O'Keefe Jr, L. Cordain, W. H. Harris, R. M. Moe, and R. Vogel Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2142 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Otto Why is aortic sclerosis associated with adverse clinical outcomes? J. Am. Coll. Cardiol., January 21, 2004; 43(2): 176 - 178. [Full Text] [PDF] |
||||
![]() |
T. E. David and J. Ivanov Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 939 - 941. [Full Text] [PDF] |
||||
![]() |
R. S. Farivar and L. H. Cohn Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 969 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
G J Morgan-Hughes, P E Owens, C A Roobottom, and A J Marshall Three dimensional volume quantification of aortic valve calcification using multislice computed tomography Heart, October 1, 2003; 89(10): 1191 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Pate, M. N. Tahir, R. T. Murphy, and J. B. Foley Anti-inflammatory Effects of Statins in Patients with Aortic Stenosis Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 201 - 206. [Abstract] [PDF] |
||||
![]() |
K.-L. Chan Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol., August 20, 2003; 42(4): 593 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Bashore and T. J. Gardner Valvular heart disease J. Am. Coll. Cardiol., July 16, 2003; 42(2): 388 - 390. [Full Text] [PDF] |
||||
![]() |
N. M Rajamannan, B. Gersh, and R. O Bonow CALCIFIC AORTIC STENOSIS: FROM BENCH TO THE BEDSIDE--EMERGING CLINICAL AND CELLULAR CONCEPTS Heart, July 1, 2003; 89(7): 801 - 805. [Full Text] [PDF] |
||||
![]() |
A. S. Pearlman Medical treatment ofaortic stenosis: Promising, or wishful thinking? J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1731 - 1734. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |